These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34767068)

  • 21. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 23. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI.
    Zhou Z; Adrada BE; Candelaria RP; Elshafeey NA; Boge M; Mohamed RM; Pashapoor S; Sun J; Xu Z; Panthi B; Son JB; Guirguis MS; Patel MM; Whitman GJ; Moseley TW; Scoggins ME; White JB; Litton JK; Valero V; Hunt KK; Tripathy D; Yang W; Wei P; Yam C; Pagel MD; Rauch GM; Ma J
    Sci Rep; 2023 Jan; 13(1):1171. PubMed ID: 36670144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI.
    Zhang MQ; Liu XP; Du Y; Zha HL; Zha XM; Wang J; Liu XA; Wang SJ; Zou QG; Zhang JL; Li CY
    Br J Radiol; 2024 Jan; 97(1153):228-236. PubMed ID: 38263817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
    Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
    Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer.
    Yoen H; Kim SY; Lee DW; Lee HB; Cho N
    Korean J Radiol; 2023 Jul; 24(7):626-639. PubMed ID: 37404105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
    Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preoperative radiogenomic model based on quantitative heterogeneity for predicting outcomes in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy.
    Zhou J; Bai Y; Zhang Y; Wang Z; Sun S; Lin L; Gu Y; You C
    Cancer Imaging; 2024 Jul; 24(1):98. PubMed ID: 39080809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of triple negative breast cancer based on DCE-MRI multi-phase full-volume ROI clinical radiomics model.
    Qi X; Wang W; Pan S; Liu G; Xia L; Duan S; He Y
    Acta Radiol; 2024 Feb; 65(2):173-184. PubMed ID: 38017694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
    Wu J; Gong G; Cui Y; Li R
    J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of triple-negative breast cancer and androgen receptor expression based on histogram and texture analysis of dynamic contrast-enhanced MRI.
    Xu WJ; Zheng BJ; Lu J; Liu SY; Li HL
    BMC Med Imaging; 2023 Jun; 23(1):70. PubMed ID: 37264313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.
    Han X; Yang H; Jin S; Sun Y; Zhang H; Shan M; Cheng W
    Cancer Med; 2023 Jan; 12(2):1389-1398. PubMed ID: 35822639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
    Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer.
    Ma M; Gan L; Jiang Y; Qin N; Li C; Zhang Y; Wang X
    Comput Math Methods Med; 2021; 2021():2140465. PubMed ID: 34422088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
    Liang X; Chen X; Yang Z; Liao Y; Wang M; Li Y; Fan W; Dai Z; Zhang Y
    BMC Cancer; 2022 Dec; 22(1):1250. PubMed ID: 36460972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Wang W; Wang X; Liu J; Zhu Q; Wang X; Wang P
    Chin Med J (Engl); 2021 Dec; 135(3):333-340. PubMed ID: 35108228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.
    Li ZY; Wang XD; Li M; Liu XJ; Ye Z; Song B; Yuan F; Yuan Y; Xia CC; Zhang X; Li Q
    World J Gastroenterol; 2020 May; 26(19):2388-2402. PubMed ID: 32476800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
    Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
    Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.
    Jimenez JE; Abdelhafez A; Mittendorf EA; Elshafeey N; Yung JP; Litton JK; Adrada BE; Candelaria RP; White J; Thompson AM; Huo L; Wei P; Tripathy D; Valero V; Yam C; Hazle JD; Moulder SL; Yang WT; Rauch GM
    Eur J Radiol; 2022 Apr; 149():110220. PubMed ID: 35193025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a nomogram model based on pretreatment ultrasound and contrast-enhanced ultrasound to predict the efficacy of neoadjuvant chemotherapy in patients with borderline resectable or locally advanced pancreatic cancer.
    Yan X; Fu X; Gui Y; Chen X; Cheng Y; Dai M; Wang W; Xiao M; Tan L; Zhang J; Shao Y; Wang H; Chang X; Lv K
    Cancer Imaging; 2024 Jan; 24(1):13. PubMed ID: 38245789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.